Scarica l'app Stockscreener
154.81
3.00%
-4.78
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Insmed Inc Borsa (INSM) Ultime notizie
Insmed (INSM): Top QQQ Stock to Buy Now - Yahoo Finance
Insmed Achieves $280 Million Trading Volume, Secures Leading Market Position Despite Positive Analyst Ratings and Clinical Challenges - Bitget
Here Are Friday’s Top Wall Street Analyst Research Calls: Autodesk, Delek US Holdings, Insmed, Nike, Nutanix, ServiceNow, Shake Shack, Southern Copper, Veeva Systems, and More - 24/7 Wall St.
Is It Too Late To Consider Insmed (INSM) After A 146% One Year Surge? - Yahoo Finance
Insmed (INSM) poised for 2026 upside with potential $1.3B Arikayce sales boost, Roth/MKM initiates buy - MSN
FRANKLIN GROWTH OPPORTUNITIES FUND's Insmed Inc(INSM) Holding History - GuruFocus
Insmed (INSM) Halts Brensocatib R&D After Trial Setback - GuruFocus
Insmed chair and CEO William Lewis sells $1.75 million in stock - Investing.com
Insmed Insider Sold Shares Worth $1,746,336, According to a Recent SEC Filing - Moomoo
Insmed (INSM) CEO sells shares, exercises options under 10b5-1 plan - Stock Titan
Insmed Incorporated (INSM): Billionaire Stan Druckenmiller Trims Stake - Yahoo Finance
Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire Inc.
Insmed Ends Brinsupri Development in Skin Disease Post Study Failure - Yahoo Finance
Insmed Drug Misses Primary Goal, Program Axed - Benzinga
Insmed Discontinues Brensocatib HS Program After Phase 2b CEDAR Study Fails to Meet Endpoints - Minichart
AVIP AB Mid Cap Core Portfolio's Insmed Inc(INSM) Holding History - GuruFocus
Insmed (INSM) Maintains Buy Rating Despite Trial Setback - GuruFocus
Insmed (INSM) to Resume Trading After Phase 2b Study Results - GuruFocus
Insmed (INSM) Shares Dip 2% After Trading Resumes - GuruFocus
Insmed (INSM) Halts Brensocatib Development for Hidradenitis Sup - GuruFocus
Insmed stock falls after failed hidradenitis suppurativa trial By Investing.com - Investing.com Canada
Insmed announced that its latest study failed to meet both the predefined primary and secondary efficacy endpoints. - Bitget
Brensocatib HS trial misses endpoints as Insmed (INSM) shuts CEDAR program - Stock Titan
Insmed Provides Clinical Update on Phase 2b CEDAR Study - PR Newswire
Net current asset value per share of Insmed Incorporated – BX:IM8N - TradingView
RBC Capital Adjusts Price Target on Insmed to $212 From $203, Maintains Outperform Rating - Moomoo
Proposed Common stock sale by INSM (NASDAQ: INSM) with insider William Lewis activity - Stock Titan
Market Rankings: What are the risks of holding Insmed Incorporated2026 Support & Resistance & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Cacchillo v. Insmed Inc. - Law.com
Aberdeen Group plc Buys 18,490 Shares of Insmed, Inc. $INSM - MarketBeat
Insmed Stock Jumps 29% on Encouraging PAH Study Results - MSN
141,517 Shares in Insmed, Inc. $INSM Purchased by Perpetual Ltd - MarketBeat
October Effect Ltd Acquires Shares of 12,121 Insmed, Inc. $INSM - MarketBeat
Insmed, Inc. $INSM Shares Acquired by Nisa Investment Advisors LLC - MarketBeat
Insmed Incorporated (INSM) stock price, news, quote and history - Yahoo Finance Singapore
Roger Adsett Sells 88,060 Shares of Insmed (NASDAQ:INSM) Stock - MarketBeat
Insmed (INSM) COO exercises options, sells 88,060 preplanned shares - Stock Titan
Insmed (INSM) Is Up 10.0% After Positive ENCORE Data Position ARIKAYCE For Earlier MAC Use - Yahoo Finance
Insmed, Inc. $INSM Shares Sold by Allspring Global Investments Holdings LLC - MarketBeat
Quarterly Risk: Why is Insmed Incorporated stock going upMarket Activity Report & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Insmed Inc. R (IM8N.DU) Stock Price, News, Quote & History - ca.finance.yahoo.com
Insmed (NASDAQ:INSM) Insider Michael Alexander Smith Sells 19,638 Shares - MarketBeat
INSM Stock Price, Quote & Chart | INSMED INC (NASDAQ:INSM) - ChartMill
Insmed, Inc. (NASDAQ:INSM) Receives Average Rating of "Buy" from Analysts - MarketBeat
Barclays Raises Price Target for Insmed (INSM) to $237 | INSM St - GuruFocus
INSM (NASDAQ: INSM) insider lists proposed Common share sales in Form 144 - Stock Titan
[ARS] INSMED Inc SEC Filing - Stock Titan
Insmed (NASDAQ: INSM) details $606M revenue and 150% stock gain - Stock Titan
Options Bulls Could Be Right About This Pharma Stock - Finviz
INSMED (INSM) CLO exercises options and sells 19,638 shares under 10b5-1 plan - Stock Titan
Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (AQST) and Insmed (INSM) - The Globe and Mail
Insmed Shares Surge as Arikayce Trial Results Boost Investor Confidence - StocksToTrade
Stifel Lifts PT on Insmed Incorporated (INSM) to $208 From $205 – Here’s Why - Yahoo Finance
Insmed (INSM) jumps as Morgan Stanley raises PT by 28% - MSN
Insmed (INSM) Soars 5.5%: Is Further Upside Left in the Stock? - Yahoo Finance
1.20%
3.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):